← board
BFRI
Biofrontera Inc.distress 3/10 · well-funded / low risk$1.05-3%today-9% from 52w high
Dermatology 1
Lead: Acne Vulgaris
Revenue
$10M
Liquidity
$6M
Runway
0.7 yrs
Shares 1y
+20%
Price & events
+5.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.8%
1D
-5.4%
1W
+1.9%
1M
+1.9%
3M
+5.0%
6M
-2.8%
1Y
+2.6%
2Y
—
5Y
-98.8%
All
Overview
- Market Cap
- $13.44M
- Volume
- 26.69K
- 52 Week Range
- $0.57 – $1.16
- Total Shares
- 12.80M
- Float Shares
- 9.08M
- Short %
- 0.23%
- % Held by Insiders
- 13.18%
- % Held by Institutions
- 22.42%
- RVOL
- 0.08x
- Beta
- 0.82
Pipeline stages · 2 programs
BF-200 ALA and red light LED lamp, Vehicle and red light LED lamp
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
1h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), 1h Incubation Photodynami
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-09-03 | Phase 3 | BF-200 ALA and red light LED lamp, Vehicle and red light LED lamp | Actinic Keratoses | 172 | active not recruiting |
| 2025-08-22 | Phase 2 | 1h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), 1h Incubation Photodynami | Acne Vulgaris | 126 | active not recruiting |
Catalyst news & presentations · 4
- third quarter of 2026Guided 70%regulatory submissionFiled (NDA/BLA)Ameluz PDT · Supplemental New Drug Application (sNDA) to FDASEC 8-K
- Q3 2026Guided 70%conferencedata presentationsecondaryPhase 2Ameluz® PDT · Plans to present Phase 2b data to FDA to discuss next steps.SEC 8-K
- 2026-08-12earningsEarningsEarnings releaseyahoo
- end of Q2 / early Q3 2025regulatory submissionFiled (NDA/BLA)Ameluz · FDA submission for Ameluz-PDT for sBCCSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 12,803,344 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-05-19BenchmarkBuy → Speculative Buy
- 2025-05-19BenchmarkBuy
- 2024-11-15BenchmarkBuy
- 2024-08-16BenchmarkBuy
Competitors — Acne Vulgaris
Recent news
- 2026-07-20Biofrontera targets cash flow breakeven in 2026 while aiming for 80%-85% gross margin - MSN
- 2026-07-14Biofrontera Inc. Warrants (BFRIW) Holds Steady at $0.03 – Tight Range Signals Stalemate for Penny-Stock Warrants - Fear Greed Index - dars.gov.et
- 2026-07-11Biofrontera Inc. (BFRI) Slides 3.5% as Stock Tests Key Support Near $1.04 - Liquidity Sweep - dars.gov.et
- 2026-07-11Biofrontera Inc. (BFRI) Slides 3.5% as Stock Tests Key Support Near $1.04 - Hagopian Line - dars.gov.et
- 2026-07-11Enterprise value to EBIT forward of Biofrontera Inc. – NASDAQ:BFRI - TradingView
- 2026-07-08Biofrontera’s Acne PDT Trial Completion: What Investors Should Watch Next - TipRanks
- 2026-07-08Biofrontera (BFRI) Q4 2025 earnings summary - Quartr
- 2026-07-08Biofrontera (BFRI) AGM 2026 Summary - Quartr
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.